Logo image of BLFS

BIOLIFE SOLUTIONS INC (BLFS) Stock Fundamental Analysis

NASDAQ:BLFS - US09062W2044 - Common Stock

24.92 USD
-0.51 (-2.01%)
Last: 8/28/2025, 4:11:39 PM
24.92 USD
0 (0%)
After Hours: 8/28/2025, 4:11:39 PM
Fundamental Rating

4

Taking everything into account, BLFS scores 4 out of 10 in our fundamental rating. BLFS was compared to 54 industry peers in the Life Sciences Tools & Services industry. BLFS has a great financial health rating, but its profitability evaluates not so good. BLFS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BLFS was profitable.
In the past year BLFS had a positive cash flow from operations.
BLFS had negative earnings in 4 of the past 5 years.
In multiple years BLFS reported negative operating cash flow during the last 5 years.
BLFS Yearly Net Income VS EBIT VS OCF VS FCFBLFS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

With a Return On Assets value of -1.43%, BLFS perfoms like the industry average, outperforming 53.70% of the companies in the same industry.
BLFS has a Return On Equity of -1.59%. This is comparable to the rest of the industry: BLFS outperforms 59.26% of its industry peers.
Industry RankSector Rank
ROA -1.43%
ROE -1.59%
ROIC N/A
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
BLFS Yearly ROA, ROE, ROICBLFS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

BLFS has a Gross Margin of 66.32%. This is amongst the best in the industry. BLFS outperforms 90.74% of its industry peers.
BLFS's Gross Margin has been stable in the last couple of years.
BLFS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
BLFS Yearly Profit, Operating, Gross MarginsBLFS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

8

2. Health

2.1 Basic Checks

BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLFS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BLFS has been increased compared to 5 years ago.
BLFS has a better debt/assets ratio than last year.
BLFS Yearly Shares OutstandingBLFS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BLFS Yearly Total Debt VS Total AssetsBLFS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

BLFS has an Altman-Z score of 17.48. This indicates that BLFS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BLFS (17.48) is better than 100.00% of its industry peers.
BLFS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 29.48
Altman-Z 17.48
ROIC/WACCN/A
WACC10.53%
BLFS Yearly LT Debt VS Equity VS FCFBLFS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 4.43 indicates that BLFS has no problem at all paying its short term obligations.
The Current ratio of BLFS (4.43) is better than 66.67% of its industry peers.
BLFS has a Quick Ratio of 3.45. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
BLFS has a better Quick ratio (3.45) than 64.81% of its industry peers.
Industry RankSector Rank
Current Ratio 4.43
Quick Ratio 3.45
BLFS Yearly Current Assets VS Current LiabilitesBLFS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 115.04% over the past year.
BLFS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.62%.
Measured over the past years, BLFS shows a very strong growth in Revenue. The Revenue has been growing by 24.59% on average per year.
EPS 1Y (TTM)115.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98%
Revenue 1Y (TTM)-24.62%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-10.26%

3.2 Future

BLFS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.26% yearly.
BLFS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.24% yearly.
EPS Next Y41.71%
EPS Next 2Y47.87%
EPS Next 3Y43.26%
EPS Next 5YN/A
Revenue Next Year-5.07%
Revenue Next 2Y5.32%
Revenue Next 3Y10.15%
Revenue Next 5Y16.24%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BLFS Yearly Revenue VS EstimatesBLFS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
BLFS Yearly EPS VS EstimatesBLFS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 124.60 indicates a quite expensive valuation of BLFS.
The rest of the industry has a similar Price/Earnings ratio as BLFS.
Compared to an average S&P500 Price/Earnings ratio of 27.17, BLFS is valued quite expensively.
BLFS is valuated quite expensively with a Price/Forward Earnings ratio of 261.77.
BLFS's Price/Forward Earnings is on the same level as the industry average.
BLFS's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.78.
Industry RankSector Rank
PE 124.6
Fwd PE 261.77
BLFS Price Earnings VS Forward Price EarningsBLFS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200 250

4.2 Price Multiples

BLFS's Enterprise Value to EBITDA ratio is in line with the industry average.
The rest of the industry has a similar Price/Free Cash Flow ratio as BLFS.
Industry RankSector Rank
P/FCF 3501.22
EV/EBITDA 256.61
BLFS Per share dataBLFS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BLFS's earnings are expected to grow with 43.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.99
PEG (5Y)N/A
EPS Next 2Y47.87%
EPS Next 3Y43.26%

More info and screens

0

5. Dividend

5.1 Amount

BLFS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOLIFE SOLUTIONS INC

NASDAQ:BLFS (8/28/2025, 4:11:39 PM)

After market: 24.92 0 (0%)

24.92

-0.51 (-2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners98.72%
Inst Owner Change1.47%
Ins Owners2.24%
Ins Owner Change2.65%
Market Cap1.19B
Analysts83.75
Price Target31.93 (28.13%)
Short Float %8.46%
Short Ratio6.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77%
Min EPS beat(2)72.55%
Max EPS beat(2)81.45%
EPS beat(4)4
Avg EPS beat(4)176.37%
Min EPS beat(4)55%
Max EPS beat(4)496.49%
EPS beat(8)7
Avg EPS beat(8)64.23%
EPS beat(12)7
Avg EPS beat(12)-13.03%
EPS beat(16)10
Avg EPS beat(16)-4.16%
Revenue beat(2)2
Avg Revenue beat(2)5.37%
Min Revenue beat(2)5.11%
Max Revenue beat(2)5.63%
Revenue beat(4)4
Avg Revenue beat(4)7.86%
Min Revenue beat(4)3.34%
Max Revenue beat(4)17.36%
Revenue beat(8)6
Avg Revenue beat(8)7.76%
Revenue beat(12)7
Avg Revenue beat(12)2.64%
Revenue beat(16)10
Avg Revenue beat(16)2.07%
PT rev (1m)0.25%
PT rev (3m)-0.11%
EPS NQ rev (1m)18.75%
EPS NQ rev (3m)42.21%
EPS NY rev (1m)-201.47%
EPS NY rev (3m)-217.91%
Revenue NQ rev (1m)4.59%
Revenue NQ rev (3m)2.74%
Revenue NY rev (1m)4.01%
Revenue NY rev (3m)4.01%
Valuation
Industry RankSector Rank
PE 124.6
Fwd PE 261.77
P/S 13.07
P/FCF 3501.22
P/OCF 76.82
P/B 3.44
P/tB 9.42
EV/EBITDA 256.61
EPS(TTM)0.2
EY0.8%
EPS(NY)0.1
Fwd EY0.38%
FCF(TTM)0.01
FCFY0.03%
OCF(TTM)0.32
OCFY1.3%
SpS1.91
BVpS7.25
TBVpS2.64
PEG (NY)2.99
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.43%
ROE -1.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.32%
FCFM 0.37%
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
F-Score6
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 29.48
Debt/EBITDA 0
Cap/Depr 223.97%
Cap/Sales 16.64%
Interest Coverage N/A
Cash Conversion 363.64%
Profit Quality N/A
Current Ratio 4.43
Quick Ratio 3.45
Altman-Z 17.48
F-Score6
WACC10.53%
ROIC/WACCN/A
Cap/Depr(3y)80.15%
Cap/Depr(5y)101.86%
Cap/Sales(3y)10.07%
Cap/Sales(5y)11.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)115.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98%
EPS Next Y41.71%
EPS Next 2Y47.87%
EPS Next 3Y43.26%
EPS Next 5YN/A
Revenue 1Y (TTM)-24.62%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-10.26%
Revenue Next Year-5.07%
Revenue Next 2Y5.32%
Revenue Next 3Y10.15%
Revenue Next 5Y16.24%
EBIT growth 1Y92.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year301.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y101.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1539.07%
OCF growth 3YN/A
OCF growth 5Y47.44%